Mundipharma, Purdue and Esteve partner for new pain management medicines
As part of the deal, Mundipharma and Purdue could make payments in excess of $1bn to Esteve if all development, regulatory and sales milestones are met across the
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
Axxess Pharma anticipates Canadian pharmacies expanding the TapouT line of products on their shelves. The expansion is anticipated to include TapouT supplement and protein categories, such as TapouT
The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells.
Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). The marketing application is based on data from more than 5,000 patients, including ten Phase